8-K Announcements
6Material company update
Sep 14, 2026·SEC
Material company update
Sep 10, 2026·SEC
Material company update
Jul 30, 2026·SEC
VYNE Therapeutics operates as a high-risk, clinical-stage entity where value is almost entirely dependent on the success of the VYN201 program rather than commercial operations.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 15, 2026 | -$0.08+55.6% vs -$0.18 | $86,000-57.0% vs $200,000 |
Q2 2026 Mar 12, 2026 | -$0.28-40.0% vs -$0.20 | $130,000-25.7% vs $175,000 |
Q4 2025 Nov 6, 2025 | -$0.17+10.5% vs -$0.19 | $169,000+35.2% vs $125,000 |
Q3 2025 Aug 14, 2025 | -$0.13+43.5% vs -$0.23 | $69,000-65.5% vs $200,000 |
Benchmark YARW against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Yarrow Bioscience Inc (YARW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.60 | $13.38M | -0.72 | 13.77% | -3881.54% | -70.23% | — | |
| $4.47 | $123.02M | -20.14 | 10.2% | -8.95% | -20.23% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $15.71 | $102.23M | -5.60 | -10.02% | -6.33% | -32.11% | — | |
| $0.81 | $104.64M | -0.73 | 16.8% | -41.13% | -47.28% | — | |
| $3.51 | $1.22B | 75.16 | 0.57% | 2.07% | 2.61% | — |
Yarrow Bioscience Inc (YARW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Yarrow Bioscience Inc (YARW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 14, 2026·SEC
Sep 10, 2026·SEC
Jul 30, 2026·SEC
Get notified when YARW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Yarrow Bioscience Inc (YARW) stock FAQ — growth, dividends, profitability & financials explained
Yarrow Bioscience Inc (YARW) reported $0.5M in revenue over the trailing twelve months. Revenue was $0.6M in fiscal year 2025.
Yarrow Bioscience Inc (YARW) grew revenue by 1.3% over the trailing twelve months, compared with the twelve months before.
No. Yarrow Bioscience Inc (YARW) reported a net loss of $18.7M over the trailing twelve months.
Yarrow Bioscience Inc (YARW) had a return on equity (ROE) of -70.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Yarrow Bioscience Inc (YARW) had negative free cash flow of $16.9M over the trailing twelve months.